Lite Strategy, Inc. Capital Expenditures Incurred but Not yet Paid
Lite Strategy, Inc. (LITS) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-11-12
- Lite Strategy, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Lite Strategy, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was $7.00K.
- Lite Strategy, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month |
|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2023-09-30 | $7.00K 10-Q · filed 2024-11-12 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |